Aliases & Classifications for Phototoxic Dermatitis

MalaCards integrated aliases for Phototoxic Dermatitis:

Name: Phototoxic Dermatitis 12 15
Dermatitis, Phototoxic 44 73
Photosensitisation Reaction 12
Photosensitive Dermatitis 12
Photosensitiveness 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4407
MeSH 44 D017484
NCIt 50 C4816
SNOMED-CT 68 53597009 84326006
UMLS 73 C0162830

Summaries for Phototoxic Dermatitis

MalaCards based summary : Phototoxic Dermatitis, also known as dermatitis, phototoxic, is related to photoparoxysmal response 1 and trichothiodystrophy 1, photosensitive, and has symptoms including photophobia An important gene associated with Phototoxic Dermatitis is IER3IP1 (Immediate Early Response 3 Interacting Protein 1), and among its related pathways/superpathways are Staphylococcus aureus infection and amb2 Integrin signaling. The drugs Zinc and Flavin Mononucleotide have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and lung.

Wikipedia : 76 Photodermatitis, sometimes referred to as sun poisoning or photoallergy, is a form of allergic contact... more...

Related Diseases for Phototoxic Dermatitis

Graphical network of the top 20 diseases related to Phototoxic Dermatitis:



Diseases related to Phototoxic Dermatitis

Symptoms & Phenotypes for Phototoxic Dermatitis

UMLS symptoms related to Phototoxic Dermatitis:


photophobia

Drugs & Therapeutics for Phototoxic Dermatitis

Drugs for Phototoxic Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 424)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 7440-66-6 23994
2
Flavin Mononucleotide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 146-17-8 643976
3
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
4
Copper Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 7440-50-8 27099
5
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
6
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 1 564-25-0 54671203
7
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
8
Azithromycin Approved Phase 4 83905-01-5 55185 447043
9
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13422-51-0 11953898 44475014
10
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129497-78-5
11
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
12
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
13
Epinephrine Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 51-43-4 5816
14
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-81-7 4114
15
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
16 Titanium dioxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 13463-67-7
17
Racepinephrine Approved Phase 4,Not Applicable,Early Phase 1 329-65-7 838
18
Benzophenone Approved Phase 4,Not Applicable 119-61-9 3102
19
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 7782-49-2
20
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
21
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
22
Iron Approved Phase 4,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
23
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
24
Stavudine Approved, Investigational Phase 4,Phase 2,Phase 3 3056-17-5 18283
25
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
26
Fluorouracil Approved Phase 4,Phase 3,Not Applicable 51-21-8 3385
27
Interferon beta-1b Approved Phase 4 145155-23-3
28
Oxybenzone Approved Phase 4,Not Applicable 131-57-7 4632
29
Zinc oxide Approved Phase 4 1314-13-2
30
Avobenzone Approved, Investigational Phase 4 70356-09-1
31
Rifampicin Approved Phase 4,Phase 3 13292-46-1 5458213 5381226
32
Imiquimod Approved, Investigational Phase 4,Not Applicable 99011-02-6 57469
33
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 98-92-0 936
34
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-81-7 5785 54670067
35
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 1406-16-2
37
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 11103-57-4, 68-26-8 445354
38
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13422-55-4
39
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 65-23-6 1054
40
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 59-67-6 938
41
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 1406-66-2 14986
42
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 66-72-8 1050
43
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-88-5 493570
44
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-43-8, 70-16-6 1130
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
46
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-19-9 44176380
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 59-02-9 14985
48
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
49 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 cadexomer iodine Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 561)
# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
3 Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced Unknown status NCT01661985 Phase 4 Azithromycin;Doxycycline;lymecycline
4 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
5 CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas Unknown status NCT01956474 Phase 4
6 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
7 A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests Completed NCT03406117 Phase 4 HAT1
8 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
9 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
10 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
11 Photodynamic Therapy During Supportive Periodontal Therapy Completed NCT02666573 Phase 4
12 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
13 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
14 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
15 Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Completed NCT01574430 Phase 4
16 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
17 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
18 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
19 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
20 Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Completed NCT01695356 Phase 4 290-400 nm sunscreen;290-800 nm sunscreen
21 Efficacy and Safety of Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
22 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
23 Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream Completed NCT01021787 Phase 4 Titanium dioxide
24 Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction Completed NCT02415777 Phase 4 Ursodeoxycholic acid, thiamine, riboflavin
25 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo
26 The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics Completed NCT02117869 Phase 4
27 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4 Ranibizumab;Verteporfin PDT;Sham PDT
28 Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin Completed NCT01485211 Phase 4 cross-linking with hypo-osmolar riboflavin
29 Effectiveness of Varenicline: Testing Individual Differences Completed NCT01228175 Phase 4 Placebo;Varenicline
30 Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso Completed NCT00909974 Phase 4
31 Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment Completed NCT00680498 Phase 4 Ranibizumab;Ranibizumab plus Photodynamic therapy
32 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4 Verteporfin Photodynamic Therapy;Ranibizumab
33 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
34 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
35 Initial Versus Delayed PDT Combination With Conbercept in PCV Recruiting NCT02821520 Phase 4 conbercept
36 Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Recruiting NCT02495181 Phase 4 IVT Aflibercept; Verteporfin PDT;IVT Aflibercept; Sham PDT
37 Photodynamic Therapy for Papulopustular Rosacea Recruiting NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
38 Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics Recruiting NCT03012529 Phase 4 Rifampin;Riboflavin Placebo
39 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
40 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
41 Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis Active, not recruiting NCT02409732 Phase 4 aminolevulinic acid hydrochloride
42 Aflibercept in Polypoidal Choroidal Vasculopathy Active, not recruiting NCT02120950 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
43 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
44 Epi-On Corneal Crosslinking for Keratoconus Enrolling by invitation NCT03245853 Phase 4 Riboflavin 5'-Phosphate
45 Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) Terminated NCT00134667 Phase 4 Photodynamic Therapy (PDT) with Visudyne (verteporfin);Macugen (pegaptanib sodium)
46 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
47 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
48 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
49 Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration Terminated NCT00423189 Phase 4 Ranibizumab (Lucentis);0.5mg ranibizumab
50 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4

Search NIH Clinical Center for Phototoxic Dermatitis

Cochrane evidence based reviews: dermatitis, phototoxic

Genetic Tests for Phototoxic Dermatitis

Anatomical Context for Phototoxic Dermatitis

MalaCards organs/tissues related to Phototoxic Dermatitis:

41
Skin, Brain, Lung, Eye, Testes, Liver, Prostate

Publications for Phototoxic Dermatitis

Articles related to Phototoxic Dermatitis:

(show all 11)
# Title Authors Year
1
Images in clinical medicine. Phototoxic dermatitis. ( 25099580 )
2014
2
Nine case series with phototoxic dermatitis related to Chenopodium album. ( 22241627 )
2012
3
Phototoxic dermatitis due to Chenopodium album in a child. ( 21854411 )
2011
4
Phototoxic dermatitis due to Chenopodium album in a mother and son. ( 15982237 )
2005
5
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. ( 15097966 )
2004
6
An outbreak of phototoxic dermatitis due to limes. ( 3812457 )
1987
7
Outbreak of phototoxic dermatitis from limes--Maryland. ( 3925324 )
1985
8
Phototoxic dermatitis from Sclerotinia sclerotiorum infected celery. ( 6540157 )
1984
9
Phototoxic dermatitis caused by celery infected by Sclerotinia sclerotiorum. ( 6228376 )
1983
10
Inhibition of ultraviolet and phototoxic dermatitis in the mouse. ( 82323 )
1978
11
Phototoxic dermatitis in a horse. (A case report). ( 5198169 )
1970

Variations for Phototoxic Dermatitis

Expression for Phototoxic Dermatitis

Search GEO for disease gene expression data for Phototoxic Dermatitis.

Pathways for Phototoxic Dermatitis

Pathways related to Phototoxic Dermatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.07 C3 ICAM1
2 10.94 ICAM1 KNG1
3
Show member pathways
10.78 LDHA LDHC
4 10.46 LDHA LDHC
5
Show member pathways
9.7 LDHA LDHC

GO Terms for Phototoxic Dermatitis

Biological processes related to Phototoxic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 9.26 ICAM1 TRIM21
2 pyruvate metabolic process GO:0006090 9.16 LDHA LDHC
3 carboxylic acid metabolic process GO:0019752 8.96 LDHA LDHC
4 acute inflammatory response to antigenic stimulus GO:0002438 8.62 ICAM1 IL31RA

Molecular functions related to Phototoxic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 9.16 C3 KNG1
2 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 8.96 LDHA LDHC
3 L-lactate dehydrogenase activity GO:0004459 8.62 LDHA LDHC

Sources for Phototoxic Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....